Clinical trials: Adenovirus Infections
Breast Neoplasms
Administration of Autologous Dendritic Cells (DCs) Infected With an Adenovirus Expressing Her-2
We, the researchers at Hamilton Health Sciences, have developed a novel approach to cancer therapy using transfected dendritic cells (DCs) to generate enhanced immunity to defined tumor antigens.
- Trial name
- NCT00197522
- Testing
- CD34+ derived DCs
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Hamilton Health Sciences Corporation
Adenovirus Infection
Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection
This was a Phase 3 open-label, non-randomized, multicenter study of oral brincidofovir (BCV) administered twice weekly for the treatment of adenovirus (AdV) infection detected during asymptomatic AdV viremia or during symptomatic…
- Trial name
- NCT02087306
- Testing
- Brincidofovir
- Where
- 33 sites in United States
- Volunteers
- 201 people
- Sponsor
- Jazz Pharmaceuticals
Healthy Volunteer
Intranasal AD4-H5-VTN as an Adenovirus Vaccine
Background: Adenoviruses are viruses that typically cause symptoms of a cold or eye infection. These viruses are being tested as part of a possible new vaccine.
- Trial name
- NCT01806909
- Testing
- Ad4-H5-Vtn
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation
This study is a randomized, double-blind, placebo-controlled I/II clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation in adults 18…
- Trial name
- NCT04840992
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- China
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Adenovirus Infection, EBV
A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®
To assess the feasibility of donor-derived interferon (IFN)-γ positive select-ed virus-specific T-cells using the cytokine capture system® (CCS) and the safety of subsequent infusion in recipients of hematopoietic stem cell…
- Conditions
- Adenovirus Infection, EBV, Cytomegalovirus Infections, Cytokine Capture System
- Trial name
- CCS (NCT02007356)
- Testing
- IFN-γ positive selected T-cells
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University Hospital, Basel, Switzerland
NEPHROSIS, LIPOID
Latent Viral Infection of Lymphoid Cells in Idiopathic Nephrotic Syndrome
The primary purpose of the study is to evaluate the association of a latent infection of lymphoid cells during the first manifestation of steroid sensitive nephrite syndrome.
- Trial name
- Nephrovir (NCT00577525)
- Where
- France
- Volunteers
- 401 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
ICH - Intracerebral Hemorrhage
Epidemiology of Intracerebral Hemorrhage
Exploring the risk factors and associations of intracerebral hemorrhage
- Trial name
- ICH (NCT06654544)
- Volunteers
- 60 people
- Sponsor
- Assiut University
Covid19
A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers
This is a single-centre, open-label, first-in-human, single ascending dose and multiple dose study to assess the safety, reactogenicity, and immunogenicity of the SC-Ad6-1 investigational product when administered via the…
- Trial name
- NCT04839042
- Testing
- SC-Ad6-1
- Where
- Australia
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Moat Biotechnology Corporation
Adenovirus
A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304
The objective is data collection to determine background rates of adenovirus (AdV) progression and mortality in subjects with Adenovirus (AdV) infection and/or disease.
- Trial name
- NCT02420080
- Testing
- Brincidofovir
- Where
- 22 sites in United States
- Volunteers
- 100 people
- Sponsor
- Jazz Pharmaceuticals
Ebola Virus Disease
Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo
The purpose of this study is the evaluation of the safety and immunogenicity of two candidate Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo, in a 2-dose heterologous regimen.
- Trial name
- EBOVAC-Salone (NCT02509494)
- Testing
- Ad26.ZEBOV, MVA-BN-Filo, MenACWY
- Where
- Sierra Leone
- Volunteers
- 1,023 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19
A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults
This is a clinical trial to evaluate the safety and immunogenicity of a recombinant adenovirus 5 vectored COVID-19 vaccine (Ad5-nCoV) with two doses and with different adminstration routes in healthy adults aged 18 years and…
- Trial name
- NCT04552366
- Testing
- Ad5-nCoV
- Where
- China
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China
Hemorrhagic Fever, Ebola
Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
The purpose of this study is to assess the safety, tolerability and immunogenicity of different vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens in healthy and…
- Trial name
- NCT02598388
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in United States, Kenya and 4 more
- Volunteers
- 578 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Viral Infection
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
The subjects eligible for this trial have a type of blood cell cancer, other blood disease or a genetic disease for which they will receive a stem cell transplant.
- Trial name
- ARMS (NCT01570283)
- Testing
- Multivirus-specific T cells Dose Level 1, Multivirus-specific T cells Dose Level 2, Multivirus-specific T cells Dose Level 3
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- AlloVir
Adenovirus Infection
Clinical Grade Adenovirus Specific T Cells for Immunotherapy After Allogeneic Stem Cell Transplantation (CTL-ADV)
Fourteen patients will be included for infusion of adenovirus-specific T-cells generated by a clinical grade IFN-γ based immunomagnetic isolation from a leukapheresis from their original donor or a haploidentical donor, in case…
- Trial name
- CTL-ADV (NCT02851576)
- Testing
- Infusion of ADV specific T cells
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Central Hospital, Nancy, France
Viral Conjunctivitis
ADenoVirus Initiative Study in Epidemiology in France
The objectives of this study is to assess the characteristics and frequency of adenovirus conjunctivitis in a population of male and female patients from one year of age who present signs and symptoms of acute conjunctivitis.
- Trial name
- NCT02054234
- Where
- 19 sites in France
- Volunteers
- 357 people
- Sponsor
- NicOx
Malignant Glioma of Brain, Glioblastoma
ADV-TK Improves Outcome of Recurrent High-Grade Glioma
Malignant gliomas are the most common primary brain tumor in adults, but the prognosis for patients with these tumors remains poor despite advances in diagnosis and standard therapies such as surgery, radiation therapy, and…
- Trial name
- HGG-01 (NCT00870181)
- Testing
- ADV-TK/GCV, Surgery, systemic chemotherapy
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Huazhong University of Science and Technology
Hepatocellular Carcinoma, Liver Transplantation
Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma
Previous rather poor results in liver transplantation (LT) of patients with advanced hepatocellular carcinoma (HCC) have made the application of LT very limited in treatment of HCC.
- Trial name
- NCT00300521
- Testing
- ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing Chao Yang Hospital
Liver Cancer, Hepatocellular Carcinoma
Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma
HCC patients with tumors >5 cm in diameter, regardless of involvement in the intrahepatic and extrahepatic portal branches participated in the study.
- Trial name
- NCT02202564
- Testing
- LT, ADV-TK, ganciclovir
- Volunteers
- 81 people
- Sponsor
- Huazhong University of Science and Technology
H5N1 Influenza
Experimental AD4-H5-VTN Vaccine in Healthy Volunteers
This is a Phase 1 randomized, single center, dose-escalation study designed to evaluate the safety and immunogenicity of live, replication competent recombinant Adenovirus type 4-H5N1Influenza Vietnam 1194 Hemagglutinin (HA)…
- Trial name
- NCT01443936
- Testing
- Ad4-H5-VTN vaccination-tonsillar route, Ad4-H5-vaccination-oral route
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Recurrent High-grade Glioma
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
This study is a single-arm, open-label, dose-escalation and dose-expanding Phase Ⅰb/Ⅱ clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12…
- Trial name
- NCT06763965
- Testing
- BioTTT001 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Bio-Targeting Therapeutics Technology Co., Ltd